Hepatitis B virus genotype B has an earlier emergence of lamivudine resistance than genotype C
- 1 November 2009
- journal article
- research article
- Published by SAGE Publications in Antiviral Therapy
- Vol. 14 (8), 1157-1163
- https://doi.org/10.3851/imp1454
Abstract
Background: Hepatitis B virus (HBV) genotype B and C seem not to affect the therapeutic response to lamivudine (3TC). Whether a given genotype has an earlier emergence of 3TC resistance remains unclear. We thus conducted this study to elucidate the association of HBV genotype with the emergence of 3TC-resistant strains in Taiwanese patients. Methods: Forty chronic hepatitis B patients who developed resistance after 3TC therapy were retrospectively enrolled. HBV genotype, serum alanine aminotransferase (ALT) and HBV DNA levels were determined at baseline. The presence of 3TC-resistant mutations was confirmed by direct sequencing whenever biochemical breakthrough developed. Results: The distribution of HBV genotype B and C in 40 patients receiving 3TC therapy were 60% and 40%, respectively. The mean interval to detect 3TC- resistant strain was 19.6 ±1.7 months. By using multivariate analysis, HBV genotype B and higher pre-treatment HBV DNA level were independently associated with earlier detection of 3TC-resistant strains. In addition, genotype B was significantly associated with development of 3TC resistance within the first 12 months of 3TC therapy compared with genotype C (odds ratio 8.27; P=0.004). Conclusions: Compared with HBV genotype C, genotype B appears to have an earlier biochemical resistance to 3TC than genotype C. Therefore, more frequent monitoring of viral load or genotypical resistance might be needed for patients with HBV genotype B infection receiving 3TC therapy, especially during the first year.Keywords
This publication has 45 references indexed in Scilit:
- Clearance of Hepatitis B e Antigen in Patients With Chronic Hepatitis B and Genotypes A, B, C, D, and FGastroenterology, 2007
- Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for managementJournal of Hepatology, 2007
- Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine‐resistant hepatitis B genotypes B and CJournal of Viral Hepatitis, 2007
- A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudineJournal of Viral Hepatitis, 2006
- Virus and transaminase levels determine the emergence of drug resistance during long-term lamivudine therapy in chronic hepatitis BJournal of Hepatology, 2005
- Clinical and virological characteristics of lamivudine resistance in chronic hepatitis B patients: A single center experienceJournal of Medical Virology, 2005
- Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysisJournal of Hepatology, 2004
- Prognostic indicators of breakthrough hepatitis during lamivudine monotherapy for chronic hepatitis B virus infectionThe Esophagus, 2004
- Lamivudine as Initial Treatment for Chronic Hepatitis B in the United StatesThe New England Journal of Medicine, 1999
- Identification and characterization of mutations in hepatitis B virus resistant to lamivudineJournal of Hepatology, 1998